20/20 Biolabs, Inc. Common Stock (AIDX) — Financial Flexibility Index
20/20 Biolabs, Inc. Common Stock (AIDX) has a Financial Flexibility Index of -0.26x as of December 2024. Free cash flow of $-536.45K (operating CF $-536.45K minus capex $0.00) represents 0% of total liabilities ($2.08 Million). Also explore AIDX net assets growth trend to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
20/20 Biolabs, Inc. Common Stock Financial Flexibility Index (2016–2024)
Historical Financial Flexibility Index trend for 20/20 Biolabs, Inc. Common Stock across 9 annual periods. Check 20/20 Biolabs, Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Annual Financial Flexibility Index for 20/20 Biolabs, Inc. Common Stock (2016–2024)
Year-by-year free cash flow to debt coverage for 20/20 Biolabs, Inc. Common Stock. For the full company profile including market capitalisation, see market value of 20/20 Biolabs, Inc. Common Stock.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.25x | $-2.60 Million | $-2.60 Million | $2.08 Million | ▲ +43.7% |
| 2023 | -2.22x | $-4.62 Million | $-4.63 Million | $2.08 Million | ▼ -204.0% |
| 2022 | 2.13x | $6.06 Million | $5.80 Million | $2.84 Million | ▲ +953.7% |
| 2021 | -0.25x | $-845.86K | $-1.07 Million | $3.38 Million | ▲ +82.6% |
| 2020 | -1.44x | $-1.85 Million | $-2.04 Million | $1.29 Million | ▲ +33.7% |
| 2019 | -2.17x | $-2.12 Million | $-2.12 Million | $976.56K | ▼ -42.5% |
| 2018 | -1.52x | $-1.25 Million | $-1.31 Million | $820.54K | ▼ -38.8% |
| 2017 | -1.10x | $-1.06 Million | $-1.06 Million | $965.94K | ▲ +67.4% |
| 2016 | -3.37x | $-1.89 Million | $-1.89 Million | $561.95K | — |